Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer

BJU International

Volumn 88, Issue 6, 2001, Pages 545-550

  Blijenberg, B G ^a   Yurdakul, G ^a   Van Zelst, B D ^a   Bangma, C H ^a   Wildhagen, M F ^a   Schroder F H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biopsy thresholds; Clinical decision making; Free PSA; PSA assays; Total PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ARTICLE; ASSAY; CALIBRATION; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; CORRELATION COEFFICIENT; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR BIOPSY;

BIOPSY; DECISION MAKING; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0035729131     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.02374.x     Document Type: Article

References (29)

1. Comparison of a polyclonal and a monoclonal immunoassay for PSA. Need for a international antigen standard
2. Prostate-specific antigen: Problems in analysis
3. Issues on standardization of prostate-specific antigen: A review
4. Standardization of PSA assays: Proposals and practical limitations
5. The second Stanford conference on international standardization of prostate-specific antigen assays
6. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values
7. New developments in the standardization of total prostate-specific antigen
8. The European Randomized Study of Screening for Prostate Cancer (ERSPC)
9. Changing role of 3 screening modalities in the European study of screening for prostate cancer (Rotterdam)
10. The European randomized study of screening for prostate cancer international cooperation and preliminary data
11. European randomized study of screening for prostate cancer - The Rotterdam pilot studies
12. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays
13. A comparison of six commercial assays for total and free prostate-specific antigen (PSA): The predictive value of the ratio free to total PSA
14. A new biomedical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I
15. Statistical methods for assessing agreement between two methods of clinical measurement
16. The clinical impact of different assays for prostate-specific antigen
17. Prostate-specific antigen: A decade of discovery - What we have learned and where we are going
18. Measurement of prostate-specific antigen (PSA) in serum by a two-site immunometric method (Hybritech Tandem-R/Tandem-E PSA)
19. Prostate cancer detection in men with serum concentrations of 2.6-4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements
20. Diagnostic value of percent free prostate-specific antigen: Retrospective analysis of a population-based screening study with emphasis on men with PSA levels less then 3.0 ng/mL
21. Lowering PSA cutoffs to enhance detection of curable prostate cancer
22. Prostate cancer detection at low prostate-specific antigen
23. Reference material for PSA. The IFCC standardization study
24. On the standardization of total prostate-specific antigen: An exercise with two reference preparations
25. Reference reagents for prostate-specific antigen (PSA): Establishment of the first international standards for free PSA and PSA(90:10)
26. 1-protease inhibitor
27. Summary report of the TD-3 workshop: Characterization of 83 antibodies against prostate-specific antigen
28. 1-antichymotrypsin in blood samples